ADC Therapeutics

ADC Therapeutics is a commercial-stage global leader in the development and commercialization of antibody-drug conjugates (ADCs), a targeted cancer therapy approach. The company focuses on hematologic malignancies and solid tumors. Their flagship product, ZYNLONTA, received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ADC Therapeutics has a robust pipeline of ADCs in clinical and preclinical development, including ADCT-602 targeting CD22 and Mipasetamab uzoptirine (ADCT-601) targeting AXL.

Beyond ZYNLONTA, ADC Therapeutics is actively investing in research and development to advance its ADC platform. The company is also focused on expanding its commercial reach through strategic partnerships and collaborations. They have a strong global presence with operations in Lausanne, Switzerland, London, and New Jersey. The company is committed to confronting cancer with the full potential of its science, bringing unique, targeted therapies and hope to patients and their families.

ADC Therapeutics is a leading global innovator in antibody drug conjugates (ADCs), a type of targeted cancer therapy. Their mission is to become a leading ADC company that transforms the lives of those impacted by cancer by developing and commercializing novel ADCs that selectively deliver potent cytotoxins directly to tumor cells, maximizing activity in tumor cells while minimizing toxicity to healthy cells. They are dedicated to expanding their portfolio, accelerating development, and prioritizing disciplined capital allocation while advancing the most promising candidates in both hematology and solid tumors.

ADC Therapeutics promotes a culture of integrity, creativity, accountability, collaboration, and urgency. They emphasize an entrepreneurial spirit and value a highly skilled global workforce committed to transforming the lives of patients with cancer. The company believes in ethical and authentic approaches, fostering innovation and partnership to achieve better outcomes. This culture is driven by a sense of purpose, striving to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer.

ADC Therapeutics prioritizes diversity, equity, and inclusion in its mission to transform lives impacted by cancer. They emphasize a culture of collaboration and belonging, aiming to attract and retain a global workforce that reflects the diversity of the patient population they serve. This commitment is evident through their dedication to building an inclusive workplace where everyone feels valued, respected, and empowered to contribute their unique perspectives and talents.